<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04807231</url>
  </required_header>
  <id_info>
    <org_study_id>PI2021_843_0044</org_study_id>
    <nct_id>NCT04807231</nct_id>
  </id_info>
  <brief_title>Comparison Between Calculated Bioavailable Testosterone Level With Radio-immunoassay Result.</brief_title>
  <acronym>TESTOBIO</acronym>
  <official_title>Comparison Between Calculated Bioavailable Testosterone Level With Radio-immunoassay Result.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Centre Hospitalier Universitaire, Amiens</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Centre Hospitalier Universitaire, Amiens</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Currently, the gold standard to obtain bioavailable testosterone results is radioimmunoassay&#xD;
      (RIA). However, this assay requires specific equipment.&#xD;
&#xD;
      Giton in 2006 proposed an optimized calculation of the Vermeulen equation, the results of&#xD;
      which seem to be well correlated with those obtained by RIA.&#xD;
&#xD;
      The aim of this study is to determine if the bioavailable testosterone levels determined by&#xD;
      both methods are similar in order to replace the usual RIA assay of bioavailable testosterone&#xD;
      by this calculation.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">March 11, 2021</start_date>
  <completion_date type="Anticipated">March 2023</completion_date>
  <primary_completion_date type="Anticipated">March 2023</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Case-Only</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Concordance between RIA and calculated testosterone level</measure>
    <time_frame>2 years</time_frame>
    <description>Concordance between RIA and calculated testosterone level</description>
  </primary_outcome>
  <enrollment type="Anticipated">270</enrollment>
  <condition>Testosterone</condition>
  <condition>Androgens</condition>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Blood withdrawal</intervention_name>
    <description>Blood withdrawal in order to perform a bioavailable testosterone RIA (Radio-Immuno Assay).</description>
  </intervention>
  <biospec_retention>Samples Without DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      Blood sample in order to perform a bioavailable testosterone Radio-Immuno Assay&#xD;
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        The population of this study is a unique cohort of 270 patients, male and female, aged&#xD;
        between 18 and 90 (included).&#xD;
&#xD;
        These patients have been included if there were being prescribed bioavailable testosterone&#xD;
        by their physician in routine.&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Every men and women aged between 18 and 90 can be included&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  insufficient sample&#xD;
&#xD;
          -  sample not send for RIA&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>90 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Marion SOYEZ, DR</last_name>
    <phone>03 22 08 71 02</phone>
    <email>Soyez.Marion@chu-amiens.fr</email>
  </overall_contact>
  <location>
    <facility>
      <name>CHU Amiens</name>
      <address>
        <city>Amiens</city>
        <zip>80480</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Marion SOYEZ, MD</last_name>
      <phone>03 22 08 71 02.</phone>
      <email>Soyez.Marion@chu-amiens.fr</email>
    </contact>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>March 2021</verification_date>
  <study_first_submitted>March 11, 2021</study_first_submitted>
  <study_first_submitted_qc>March 17, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">March 19, 2021</study_first_posted>
  <last_update_submitted>March 17, 2021</last_update_submitted>
  <last_update_submitted_qc>March 17, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">March 19, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>testosterone</keyword>
  <keyword>androgens</keyword>
  <keyword>men</keyword>
  <keyword>women</keyword>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

